NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance of A549/DDP cells

Cancer Cell International

Youguo Huang¹  Jinfeng Wang¹  Yufeng Tong¹  Zhenhua Huang¹ 

[1] National Laboratory of Biomacromolecules, Center for Molecular Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

关键词: ³¹P-NMR;    ¹H-NMR;    membrane lipids;    cisplatin;    A549 cells;   

Others  :  796102
DOI  :  10.1186/1475-2867-3-5

 received in 2002-11-27, accepted in 2003-04-08,  发布年份 2003

【 摘 要 】

Changes of membrane lipids in cisplatin-sensitive A549 and cisplatin-resistant A549/DDP cells during the apoptotic process induced by a clinical dose of cisplatin (30 μM) were detected by ¹H and ³¹P-NMR spectroscopy and by membrane fluidity measurement. The apoptotic phenotypes of the two cell lines were monitored with flow cytometry. The assays of apoptosis showed that significant apoptotic characteristics of the A549 cells were induced when the cells were cultured for 24 hours after treatment with cisplatin, while no apoptotic characteristic could be detected for the resistant A549/DDP cells even after 48 hours. The results of ¹H-NMR spectroscopy demonstrated that the CH₂/CH₃ and Glu/Ct ratios of the membrane of A549 cells increased significantly, but those in A549/DDP cell membranes decreased. In addition, the Chol/CH₃ and Eth/Ct ratios decreased for the former but increased for the latter cells under the same conditions. ³¹P-NMR spectroscopy indicated levels of phosphomonoesters (PME) and ATP decreased in A549 but increased in A549/DDP cells after being treated with cisplatin. These results were supported with the data obtained from ¹H-NMR measurements. The results clearly indicated that components and properties of membrane phospholipids of the two cell lines were significantly different during the apoptotic process when they were treated with a clinical dose of cisplatin. Plasma membrane fluidity changes during cisplatin treatment as detected with the fluorescence probe TMA-DPH also indicate marked difference between the two cell lines. We provided evidence that there are significant differences in plasma membrane changes during treatment of cisplatin sensitive A549 and resistant A549/DDP cells.

【 授权许可】

   
2003 Huang et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Lehnert M: Multidrug resistance in human cancer. J Neurooncol 1994, 22:239-43.
• [2]Zgurskaya HI, Nikaido H: Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 2000, 37:219-25.
• [3]Cleary I, Doherty G, Moran E, Clynes M: The multidrug-resistant human lung tumor cell line DLKP-A 10 expression novel drug accumulation and a sequestration system. Biochem Pharmacol 1997, 53:1493-502.
• [4]Clynes M, Daly C, NicAmhlaoibh R, Cronin D, Elliott C, O'Connor R, O'Doherty T, Connolly L, Howlett A, Scanlon K: Recent developments in drug resistance and apoptosis research. Crit Rev Oncol Hematol 1998, 28:181-205.
• [5]Grunicke H, Hofman J: Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol Ther 1992, 55:1-30.
• [6]Koert NJ, Burger Rutger WHM Staffhorst, Ben De Kruijiff: Interaction of the anti-cancer drug cisplatin with phosphatidylserine in intact and semi-intact cells. Biochica et Biophysica Acta 1999, 1419:43-54.
• [7]Escriba PV, Ferrer_Montiel AV, Ferragut JA, Gonzalez_Ros JM: Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry 1990, 29:7275-7282.
• [8]May GL, Wright LC, Dye M, Mackinnon WB, Fox RM, Mountford CE: Plasma lipid composition of vinblastine sensitive and resistant human leukemic lymphoblasts. Int J Cancer 1988, 42:728-733.
• [9]Litman T, Nielsen D, Skovsgaard T, Bukhave K: Lipid composition of sensitive and multidrug resistant ascites tumor cells. Cell Pharmacol 1995, 2:9-14.
• [10]Ferretti A, Knijn A, Iorio E, Pulciani S, Giambenedetti M, Molinari A, Meschini S, Stringaro A, Calcabrini A, Freitas I, Strom R, Arancia G: Podo: Biophysical and structural characterization of 1H-NMR-detectable mobile lipid domains in NIH-3T3 fibroblasts. Biochim Biophys Acta 1999, 1438:329-348.
• [11]Liang Xingjie, Huang Youguo: Alteration of membrane lipid biophysical properties and resistance of human lung adenocarcinoma A549 cells to cisplatin. Sciences in China (Series C) 2001, 44:25-32.
• [12]Patricia JudsonL, Joanna WatsonM, Paola GehrigA, Weasley FowlerC Jr, Stephen H: Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Research 1999, 59:2425-2432.
• [13]Laurence Le Moyec, Roger Tatoud, Armelle Degeorges, Cynthia Calabresse, Guy Bauza, Michel Eugene, Fabien Calvo: Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line. Cancer Research 1996, 56:3461-3467.
• [14]Foluso Adebodun, Jan PostFM: 31P NMR characterization of cellular metabolism during dexamethasone induced apoptosis in human leukemic cell lines. Journal of Cellular Physiology 1994, 158:180-186.
• [15]Ferretti G, Zolese G, Curatola G, Jezequel AM, Benedetti : Membrance heterogeneity in isolated rat hepatocytes and liver plasma membrane subfraction: a comparative study using DPH and its cationic derivative TMA-DPH. Biochimica et Biophysica Acta 1993, 1147:245-250.
• [16]Mountford CE, Mackinnon EB: Proton magnetic resonance spectroscopy of lymphocytes: an historical perspective. Immunmethods 1994, 4:98-112.
• [17]Singh JK, Dasgupta A, Adayev T, Shahmehdi SA, Hammond D, Banerjee P: Apoptosis is associated with an increase in saturated fatty acid containing phospholipids in the neuronal cell line, HN2-5. Biochim Biophys Acta 1996, 1304:171-178.
• [18]Mountford CE, Grossman G, Reid G, For RM: Characterization of transformed cells and tumor by proton nuclear magnetic resonance spectroscopy. Cancer Research 1982, 42:2270-2277.
• [19]May GL, Wright LC, Holmes KT, Williams PG, Smith ICP, Wright PE, Fox RM, Mountford CE: Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. J Biochem 1986, 261:3048-3054.
• [20]Michal Neeman, Hadassa Degani: Metabolic studies of estrogen and tamoxifen-treated human cancer cells by nuclear magnetic resonance spectroscopy. Cancer Research 1989, 49:589-594.
• [21]Liora Bogin, Moshe PapaZ, Sylvie Polak-Charcon, Hadassa Degani: TNF-induced modulations of phosphlipid metabolism in human breast cancer cells. Biochimica et Biophysica Acta 1998, 1392:217-232.
• [22]Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC: Phosphorylcholine: a novel second messenger for mitogenic activity of growth factors. Oncogene 1993, 8:2959-2968.
• [23]Dedon PC, Borch RF: Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 1987, 36:1955-1964.
• [24]Mistry P, Loh SY, Kelland LR: EVect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Int J Cancer 1993, 55:849-856.
• [25]Eastman A: Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 1987, 61:241-248.
• [26]Ishikawa T., Ali-Oaman F: Glutathione-associated cis-diammine-dichloroplatinum (II) metabolites and ATP-dependent efflux from leukemia cells. Journal of Biological Chemistry 1993, 268:20116.
• [27]Andrews PA, Murphy MP: Howell SB. DiVerential potentiation of alkylating and platinating agent cytotoxicity in human ovarian-carcinoma cells by glutathione depletion. Cancer Res 1985, 45:6250-6253.
• [28]Teicher BA, Holden SA, Kelley MJ: Characterization of a human squamous-carcinoma cell line resistant to cisp-diamminedichloroplatinum (II). Cancer Res 1987, 47:388-393.
• [29]Perez RP: Cellular and molecular determinants of cisplatin resistance. European Journal of Cancer 1998, 34:1535-1542.
• [30]Ahn H, Lee E, Kim K, Lee C: EVect of glutathione and its related enzymes on chemosensitivity of renal cell carcinoma and bladder carcinoma cell lines. J Urol 1994, 151:263-267.
• [31]Behrens BC, Hamilton TC, Masuda H: Characterization of a cis-diammine-dichloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987, 47:414-418.
• [32]Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR: The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian cancer cell lines. Br J Cancer 1991, 64:215-220.
• [33]Saint-Ruff C, Malfoy B, Scholl S, Zafrani B, Dutrillaux B: CSTp gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers. Oncogene 1991, 6:403-406.
• [34]Piotto M, Saudek V, Sklenar V: Gradient tailored excitation for single-quantum NMR-spectroscopy of aqueous-solutions. J Biomol NMR 1992, 2:661-665.
• [35]Pangdey BN, Mishra KP: Radiation induced oxidative damage modification by cholesterol in liposomal membrance. Radiation Physics and Chemistry 1999, 54:481-489.